Online inquiry

IVTScrip™ mRNA-Anti-MS4A1, AT-004(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3363MR)

This product GTTS-WQ3363MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets MS4A1 gene. The antibody can be applied in Canine B-cell lymphoma research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Caninized
RefSeq NM_001048028.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 485430
UniProt ID Q3C2E2
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MS4A1, AT-004(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ3363MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4340MR IVTScrip™ mRNA-Anti-IL5RA, BIW-8405(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BIW-8405
GTTS-WQ9331MR IVTScrip™ mRNA-Anti-TNFRSF18, INCAGN-01876(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA INCAGN-01876
GTTS-WQ9298MR IVTScrip™ mRNA-Anti-TACSTD2, IMMU-132(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA IMMU-132
GTTS-WQ10864MR IVTScrip™ mRNA-Anti-B4GALNT1, MAb-14.18(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MAb-14.18
GTTS-WQ13304MR IVTScrip™ mRNA-Anti-PTK7, PF-06523435(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA PF-06523435
GTTS-WQ13197MR IVTScrip™ mRNA-Anti-PCSK9, PF-04950615(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA PF-04950615
GTTS-WQ11831MR IVTScrip™ mRNA-Anti-LAG3, MK-4280(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MK-4280
GTTS-WQ6671MR IVTScrip™ mRNA-Anti-MUC16, DMUC5754A(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA DMUC5754A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW